Novel Targets in Ophthalmology
Background
Invasive cancer remains a predominant cause of mortality globally, responsible for approximately 13% of all deaths annually. As the global population continues to age, cancer rates have surged, highlighting a critical need for advanced therapeutic approaches. Traditional cancer treatments focus on intrinsic tumor properties, often overlooking the significant influence of the surrounding tissue environment on tumor growth. Additionally, the pathologic angiogenesis observed in conditions like cancer and proliferative retinopathy presents yet another challenge, exhibiting excessive and disorganized blood vessel growth driven by inflammatory cytokines and growth factors. While current therapies exist, they largely target only portions of these complex pathways, leaving ample room for improvement.
Similarly, diseases like age-related macular degeneration (AMD) and diabetic retinopathy are leading causes of blindness, affecting millions without a satisfactory cure. These conditions are marked by pathological neovascularization, necessitating novel interventions capable of effectively modulating abnormal blood vessel growth.
Technology Overview
The technologies from Dr. Lois Smith's lab at BCH exploit the potential of Suppressors of Cytokine Signaling (SOCS), particularly SOCS3, as a multifunctional therapeutic target. SOCS3 operates as an endogenous angiostatic regulator and tumor suppressor, capable of inhibiting pathological blood vessel growth. The technology leverages SOCS3-modulating agents, including fusion proteins, vectors, and peptidomimetics, to enhance SOCS3 expression. These agents can be used alone or in conjunction with checkpoint inhibitors, presenting a comprehensive solution to various solid tumors and angiogenesis-driven diseases.
Moreover, the technology identifies FFA1 and FGF21 as valuable targets for eye diseases, providing a pathway to ameliorate conditions like AMD and retinopathy. FGF21, in its long-acting stabilized form, extends therapeutic effects across neurovascular diseases of the eye.
Applications
- Ophthalmic Conditions: Treatment of AMD, diabetic retinopathy, retinopathy of prematurity, and macular telangiectasia.
- Pathological Angiogenesis: Prevention and treatment of aberrant blood vessel growth in various tissues.
Advantages
1. Targeted Approach: SOCS3 and FFA1/FGF21 pathways offer enhanced selectivity, focusing on pathological over physiological angiogenesis.
2. Improved Efficacy: SOCS3 modulation shows promise in significantly inhibiting tumor growth and vessel proliferation.
3. Extended Action: Stabilized FGF21 agents provide prolonged therapeutic effects, reducing dosing frequency and improving patient compliance.
4. Versatility: Applicable across a broad spectrum of diseases, addressing significant unmet medical needs in oncology and ophthalmology.
This invention promises to redefine therapeutic strategies in both oncology and ophthalmology, providing targeted, long-acting solutions to diseases characterized by pathological angiogenesis and tumor growth.
